Exelixis, Inc.

NASDAQ:EXEL

Biotechnology

Healthcare
$68.29 +0.65%

+$0.34 today

Market cap
$17.17B
Beta
0.43
P/E (TTM)
16.3
EPS (TTM)
$3.23
52W Low $33.76High $53.93

Volume 1.82M

Average 2.55M

EXEL Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Exelixis, Inc.NASDAQ: EXEL

Cash & Equivalents · Q2 FY2026 · quarter ended Jul 2026

Cash & equivalents rises 71.2% from a year ago

Cash & equivalents stood at $281.45M at the end of Q2 FY2026, up 71.2% from a year earlier and up 24.5% from the prior quarter. Over 3 fiscal years it compounded at -1.3% a year.

Context

  • Cash & equivalents amounted to 11.3% of total assets at the end of Q2 FY2026, up 5.1 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +71.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJul 2026
$281.45M+24.5% QoQ
Last fiscal yearJan 2026
$482.49M+122.0% YoY
Year agoJul 2025
$164.43M+71.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+71.2%——
1 year+122.0%——
3-year CAGR-1.3%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
482.49M USD
Year-over-year change
+122.0%
4-year CAGR
-7.1%

Cash & Equivalents vs competitors

How EXEL compares with its peers on the latest reported figures

  • EXEL's Jul 2026 cash & equivalents of $281.45M is the 5th highest of the 8 companies compared; the peer median is $815.44M.
  • Its year-over-year change of +71.2% is the 3rd highest of 8, against a peer median of -2.7%.
  • Cash & equivalents amounts to 11.3% of total assets for EXEL, versus a peer median of 12.0%.
EXEL Competitors Peer median
Cash & Equivalents for EXEL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AZNAstraZeneca PLCSep 2026$7.92B -2.7%-2.5%6.6%
INCYIncyte CorporationJun 2026$3.98B +103.7%+1.6%50.6%
GMABGenmab A/SJun 2026$1.5B +16.0%-44.3%12.0%
RVMDRevolution Medicines, Inc.Jun 2026$815.44M +102.6%+33.5%18.9%
EXELExelixis, Inc.Jul 2026$281.45M +71.2%-1.3%11.3%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$130.89M -15.0%+22.0%27.7%
HCMHUTCHMED (China) LimitedDec 2025$71.33M -53.7%-38.9%4.1%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$24.41M -46.6%+18.4%4.8%
Peer median (excluding EXEL) $815.44M-2.7%+1.6%12.0%

Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Jan 2025
FY2025
Jan 2026
Cash & Equivalents647.17M501.2M262.99M217.37M482.49M
Short-term Investments819.91M807.27M732.31M893.9M576.6M
Net Receivables285.55M214.78M237.41M265.44M286.92M
Inventory27.49M33.3M17.32M22.39M21.69M
Other Current Assets54.63M62.21M67.93M68.48M75.6M
Total Current Assets1.83B1.62B1.32B1.47B1.44B
Property, Plant & Equipment (Net)104.03M345.44M470.85M359.11M441.27M
Goodwill63.68M63.68M63.68M63.68M63.68M
Intangible Assets00000
Long-term Investments371.11M756.73M728.72M637.29M603.6M
Tax Assets111.66M231.11M361.15M420.03M292.58M
Other Non-current Assets131M55.77M000
Total Non-current Assets781.49M1.45B1.62B1.48B1.4B
Total Assets2.62B3.07B2.94B2.95B2.84B
Account Payables24.26M32.67M33.77M38.19M29.62M
Short-term Debt00000
Tax Payables00000
Deferred Revenue7.81M7.49M000
Other Current Liabilities45.55M71.44M82.12M267.22M287.5M
Total Current Liabilities337.59M324.36M394.28M403.77M405.64M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)8.74M6.58M000
Other Non-current Liabilities8.02M61.95M94.22M108.9M104.42M
Total Non-current Liabilities68.03M258.7M284.17M299.72M277.46M
Total Liabilities405.62M583.06M678.45M703.49M683.1M
Common Stock319K324K303K282K262K
Retained Earnings(216.51M)(34.23M)(173.35M)(98.65M)(76.83M)
Accumulated OCI(758K)(14.52M)(3.75M)(1.35M)3.48M
Other Stockholders Equity00000
Minority Interest00000
Total Equity2.21B2.49B2.26B2.24B2.16B
Total Debt51.27M190.17M189.94M190.82M173.04M
Net Debt(595.9M)(311.03M)(73.05M)(26.55M)(309.45M)

Exelixis, Inc.

NASDAQ:EXEL

Intrinsic Alpha fair value

Locked

Current Price

$68.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.